Sequential treatment of anti-PD-L1 therapy prior to anti-VEGFR2 therapy contributes to more significant clinical benefits in non-small cell lung cancer

Sequential treatment of anti-PD-L1 therapy prior to anti-VEGFR2 therapy contributes to more significant clinical benefits in non-small cell lung cancer

Objective: Anti-angiogenic therapy and immune checkpoint blockade therapy are currently important treatments for non-small cell lung cancer. However, the combined use of the two therapies is controversial, and few studies have investigated the effects of different time sequences of the two therapies...

Full description

Saved in:
Bibliographic Details
Main Authors: Qiao-xin Lin, Wen-wen Song, Wen-xia Xie, Yi-ting Deng, Yan-na Gong, Yi-ru Liu, Yi Tian, Wen-ya Zhao, Ling Tian, Dian-na Gu
Format: Article
Language:English
Published: Elsevier 2025-01-01
Series:Neoplasia: An International Journal for Oncology Research
Subjects:
Immune checkpoint blockade therapy
Anti-angiogenic therapy
Sequential therapy
Non-small cell lung cancer
Tumor microvessel
Tumor immune microenvironment
Online Access:http://www.sciencedirect.com/science/article/pii/S1476558624001180
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items